Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia
Fourteen patients with poor‐risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/day). No complete remissions or return to chronic phase CML were observed. A fall in the peri...
Gespeichert in:
| Veröffentlicht in: | Hematological oncology 1989-11, Vol.7 (6), p.423-427 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 427 |
|---|---|
| container_issue | 6 |
| container_start_page | 423 |
| container_title | Hematological oncology |
| container_volume | 7 |
| creator | Malik, S. T. A. Tucker, J. Rohatiner, A. Z. S. Brace, W. Lister, T. A. |
| description | Fourteen patients with poor‐risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/day). No complete remissions or return to chronic phase CML were observed. A fall in the peripheral blast count was seen in all patients with the first cycle of treatment, and with subsequent cycles in CML patients, but all responses were transient, with eventual reemergence of peripheral blasts. In some patients, there was a clear cut improvement in symptoms such as bone and splenic pain. Five of the AML patients and all of the CML patients were treated as out‐patients. In this group of patients oral idarubicin was found to be a useful drug for palliative treatment. |
| doi_str_mv | 10.1002/hon.2900070605 |
| format | Article |
| fullrecord | <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_hon_2900070605</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_WNG_P2LW93JB_J</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4075-3c37c66cacf6ac20bd96fb608d05db4d6390550d471e33c6324ce9cf153a64bc3</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi0EKtvClRuSD1yzTOzEjo9QlX5o1eUA6tGajB3WNB8rOxHsvyclq604IY00h3memdHL2Lsc1jmA-Lgb-rUwAKBBQfmCrXIwJstBmZdsBUJXGQgpXrPzlH7OlDFQnbEzUYHOK1ix_TZiy4PDONWBQs_nGneej9Hj2Pl-5EPDkabR8-7g2-GH74cp8dZPj-i7gBx791eoW0wj3-8w-SeFdnHoAy1ScM_CG_aqwTb5t8d-wb5_ufp2eZNttte3l582GRWgy0yS1KQUITUKSUDtjGpqBZWD0tWFU9JAWYIrdO6lJCVFQd5Qk5cSVVGTvGDrZS_FIaXoG7uPocN4sDnYp-TsnJx9Tm4W3i_Cfqo77074Map5_uE4x0TYNhF7CumEKV0orcSMmQX7FVp_-M9Re7O9_-eFbHFDGv3vk4vxcV4vdWkf7q_tV7F5MPLus72TfwD1a5en</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Malik, S. T. A. ; Tucker, J. ; Rohatiner, A. Z. S. ; Brace, W. ; Lister, T. A.</creator><creatorcontrib>Malik, S. T. A. ; Tucker, J. ; Rohatiner, A. Z. S. ; Brace, W. ; Lister, T. A.</creatorcontrib><description>Fourteen patients with poor‐risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/day). No complete remissions or return to chronic phase CML were observed. A fall in the peripheral blast count was seen in all patients with the first cycle of treatment, and with subsequent cycles in CML patients, but all responses were transient, with eventual reemergence of peripheral blasts. In some patients, there was a clear cut improvement in symptoms such as bone and splenic pain. Five of the AML patients and all of the CML patients were treated as out‐patients. In this group of patients oral idarubicin was found to be a useful drug for palliative treatment.</description><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.2900070605</identifier><identifier>PMID: 2807180</identifier><identifier>CODEN: HAONDL</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Acute myelogenous leukaemia ; Administration, Oral ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Blast Crisis - drug therapy ; Blood. Blood coagulation. Reticuloendothelial system ; Chronic myeloid leukaemia ; Female ; Humans ; Idarubicin ; Idarubicin - adverse effects ; Idarubicin - therapeutic use ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology ; Leukemia, Myeloid, Acute - drug therapy ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments</subject><ispartof>Hematological oncology, 1989-11, Vol.7 (6), p.423-427</ispartof><rights>Copyright © 1989 John Wiley & Sons, Ltd</rights><rights>1990 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4075-3c37c66cacf6ac20bd96fb608d05db4d6390550d471e33c6324ce9cf153a64bc3</citedby><cites>FETCH-LOGICAL-c4075-3c37c66cacf6ac20bd96fb608d05db4d6390550d471e33c6324ce9cf153a64bc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhon.2900070605$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhon.2900070605$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6746762$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2807180$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Malik, S. T. A.</creatorcontrib><creatorcontrib>Tucker, J.</creatorcontrib><creatorcontrib>Rohatiner, A. Z. S.</creatorcontrib><creatorcontrib>Brace, W.</creatorcontrib><creatorcontrib>Lister, T. A.</creatorcontrib><title>Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia</title><title>Hematological oncology</title><addtitle>Hematol. Oncol</addtitle><description>Fourteen patients with poor‐risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/day). No complete remissions or return to chronic phase CML were observed. A fall in the peripheral blast count was seen in all patients with the first cycle of treatment, and with subsequent cycles in CML patients, but all responses were transient, with eventual reemergence of peripheral blasts. In some patients, there was a clear cut improvement in symptoms such as bone and splenic pain. Five of the AML patients and all of the CML patients were treated as out‐patients. In this group of patients oral idarubicin was found to be a useful drug for palliative treatment.</description><subject>Acute myelogenous leukaemia</subject><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Blast Crisis - drug therapy</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Chronic myeloid leukaemia</subject><subject>Female</subject><subject>Humans</subject><subject>Idarubicin</subject><subject>Idarubicin - adverse effects</subject><subject>Idarubicin - therapeutic use</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhi0EKtvClRuSD1yzTOzEjo9QlX5o1eUA6tGajB3WNB8rOxHsvyclq604IY00h3memdHL2Lsc1jmA-Lgb-rUwAKBBQfmCrXIwJstBmZdsBUJXGQgpXrPzlH7OlDFQnbEzUYHOK1ix_TZiy4PDONWBQs_nGneej9Hj2Pl-5EPDkabR8-7g2-GH74cp8dZPj-i7gBx791eoW0wj3-8w-SeFdnHoAy1ScM_CG_aqwTb5t8d-wb5_ufp2eZNttte3l582GRWgy0yS1KQUITUKSUDtjGpqBZWD0tWFU9JAWYIrdO6lJCVFQd5Qk5cSVVGTvGDrZS_FIaXoG7uPocN4sDnYp-TsnJx9Tm4W3i_Cfqo77074Map5_uE4x0TYNhF7CumEKV0orcSMmQX7FVp_-M9Re7O9_-eFbHFDGv3vk4vxcV4vdWkf7q_tV7F5MPLus72TfwD1a5en</recordid><startdate>198911</startdate><enddate>198911</enddate><creator>Malik, S. T. A.</creator><creator>Tucker, J.</creator><creator>Rohatiner, A. Z. S.</creator><creator>Brace, W.</creator><creator>Lister, T. A.</creator><general>John Wiley & Sons, Ltd</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>198911</creationdate><title>Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia</title><author>Malik, S. T. A. ; Tucker, J. ; Rohatiner, A. Z. S. ; Brace, W. ; Lister, T. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4075-3c37c66cacf6ac20bd96fb608d05db4d6390550d471e33c6324ce9cf153a64bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Acute myelogenous leukaemia</topic><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Blast Crisis - drug therapy</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Chronic myeloid leukaemia</topic><topic>Female</topic><topic>Humans</topic><topic>Idarubicin</topic><topic>Idarubicin - adverse effects</topic><topic>Idarubicin - therapeutic use</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Malik, S. T. A.</creatorcontrib><creatorcontrib>Tucker, J.</creatorcontrib><creatorcontrib>Rohatiner, A. Z. S.</creatorcontrib><creatorcontrib>Brace, W.</creatorcontrib><creatorcontrib>Lister, T. A.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Malik, S. T. A.</au><au>Tucker, J.</au><au>Rohatiner, A. Z. S.</au><au>Brace, W.</au><au>Lister, T. A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia</atitle><jtitle>Hematological oncology</jtitle><addtitle>Hematol. Oncol</addtitle><date>1989-11</date><risdate>1989</risdate><volume>7</volume><issue>6</issue><spage>423</spage><epage>427</epage><pages>423-427</pages><issn>0278-0232</issn><eissn>1099-1069</eissn><coden>HAONDL</coden><abstract>Fourteen patients with poor‐risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/day). No complete remissions or return to chronic phase CML were observed. A fall in the peripheral blast count was seen in all patients with the first cycle of treatment, and with subsequent cycles in CML patients, but all responses were transient, with eventual reemergence of peripheral blasts. In some patients, there was a clear cut improvement in symptoms such as bone and splenic pain. Five of the AML patients and all of the CML patients were treated as out‐patients. In this group of patients oral idarubicin was found to be a useful drug for palliative treatment.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>2807180</pmid><doi>10.1002/hon.2900070605</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0232 |
| ispartof | Hematological oncology, 1989-11, Vol.7 (6), p.423-427 |
| issn | 0278-0232 1099-1069 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_hon_2900070605 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Acute myelogenous leukaemia Administration, Oral Adolescent Adult Aged Aged, 80 and over Biological and medical sciences Blast Crisis - drug therapy Blood. Blood coagulation. Reticuloendothelial system Chronic myeloid leukaemia Female Humans Idarubicin Idarubicin - adverse effects Idarubicin - therapeutic use Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Leukemia, Myeloid, Acute - drug therapy Male Medical sciences Middle Aged Pharmacology. Drug treatments |
| title | Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T05%3A39%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20idarubicin%20in%20the%20treatment%20of%20acute%20myelogenous%20leukaemia%20and%20the%20blast%20phase%20of%20chronic%20myeloid%20leukaemia&rft.jtitle=Hematological%20oncology&rft.au=Malik,%20S.%20T.%20A.&rft.date=1989-11&rft.volume=7&rft.issue=6&rft.spage=423&rft.epage=427&rft.pages=423-427&rft.issn=0278-0232&rft.eissn=1099-1069&rft.coden=HAONDL&rft_id=info:doi/10.1002/hon.2900070605&rft_dat=%3Cistex_cross%3Eark_67375_WNG_P2LW93JB_J%3C/istex_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/2807180&rfr_iscdi=true |